Basilea announces pediatric fosmanogepix data for IDWeek 2026

By Public Technologies
  • Basilea Pharmaceutica will present new fosmanogepix, isavuconazole and ceftobiprole data at IDWeek 2026, October 21-24, in Washington, D.C.
  • Phase 3 antifungal fosmanogepix presentations on October 23 will cover pediatric expanded-access experience in invasive mold infections and manogepix activity against Candida auris.
  • Other research will examine isavuconazole safety and treatment use, alongside ceftobiprole dosing and evidence supporting pediatric use.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Basilea Pharmaceutica AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610200115PRIMZONEFULLFEED1001278790) on October 20, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.